Biliary tract cancers: current knowledge, clinical candidates and future challenges.

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Biliary tract cancers (BTCs) are rare malignancies with a generally poor prognosis.
• Recent advances in genomic sequencing have revealed significant molecular heterogeneity within BTC subtypes.
• Understanding these molecular alterations is crucial for developing targeted therapies.

Purpose of the Study:

• To review the diverse molecular pathways in BTC, including commonly mutated genes.
• To discuss the potential of immunotherapy in BTC treatment.
• To explore the therapeutic implications of these findings for patient care.

Main Methods:

• Literature review of recent studies on BTC molecular characteristics.
• Analysis of data on genetic mutations such as KRAS, EGFR, IDH, FGFR, and BAP1.
• Evaluation of research on immune-related pathways and immunogenicity in BTC.

Main Results:

• BTC exhibits varied genetic landscapes, with specific mutations in KRAS, EGFR, IDH, FGFR, and BAP1 identified.
• Despite potential links to chronic inflammation, BTC immunogenicity is not consistently high.
• Clinical studies are investigating targeted therapies for these genetic alterations.

Conclusions:

• The molecular diversity of BTC presents both challenges and opportunities for targeted therapy.
• Immunotherapy holds potential, but its efficacy in BTC requires further investigation.
• Integrating genomic and immunotherapeutic approaches may improve BTC treatment strategies.